The aberrant buildup of misfolded proteins is a hallmark of a host of disorders, including neurodegenerative diseases such as Alzheimer's and Parkinson's. Aggregates of these toxic proteins wreak havoc on the function of ...
Jul 22, 2020
0
498
The cells of most patients' cancers are resistant to a class of drugs, called proteasome inhibitors, that should kill them. When studied in the lab, these drugs are highly effective, yet hundreds of clinical trials testing ...
May 28, 2019
0
185
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.
Sep 20, 2018
0
44
The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs. But Whitehead Institute researchers have found a mechanism underlying this resistance—a ...
Dec 27, 2016
0
61
An experimental drug that blocks the activation of an immune cell component effectively prevented rejection of heart transplants in mice, according to new research from scientists at Weill Cornell Medicine and Brigham and ...
Dec 13, 2016
0
113
A new research paper titled "GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells" has been published in Oncotarget.
Mar 6, 2024
0
0
Proteasomes are protein-degrading complexes that are important for cancer cell survival. Proteasome inhibitors are commonly used to treat diseases such as multiple myeloma and mantle cell lymphoma. Proteasomes have three ...
Dec 14, 2023
0
15
The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
Aug 16, 2023
0
1
When Yoni Silverman, now 13, was a toddler, his parents fretted as he missed milestone after milestone. The New York City couple took their son to a host of specialists, searching for answers about why he wasn't speaking ...
Mar 16, 2023
0
4
Multiple myeloma is a type of cancer that affects plasma cells, the blood cells involved in the production of antibodies. It is the second most common hematologic cancer, accounting for 2% of all cancers of hematologic origin.
Nov 9, 2022
0
14
